Group items tagged

This Funding Opportunity Announcement (FOA) invites U54 Cooperative Agreement applications aiming to establish multi-component Alzheimer Centers for the Discovery of New Medicines. The overarching purpose of this Centers program is to improve, diversify and reinvigorate the Alzheimers disease (AD) drug development pipeline by accelerating the characterization and experimental validation of next generation therapeutic targets and, integrating the targets into drug discovery campaigns. In addition, this program aims to de-risk potential therapeutics to the point that industry will invest in them, accelerating the delivery of new drugs to AD patients. To this end, the funded Centers will design, develop and disseminate tools that support target enabling packages (TEPs) for the experimental validation of novel, next generation therapeutic targets, including those emanating from the NIA-funded, target discovery programs such as AMP-AD and, initiate early stage drug discovery campaigns against the enabled targets.

This Funding Opportunity Announcement (FOA) invites U54 Cooperative Agreement applications aiming to establish multi-component Alzheimer Centers for the Discovery of New Medicines. The overarching purpose of this Centers program is to improve, diversify and reinvigorate the Alzheimer's disease (AD) drug development pipeline by accelerating the characterization and experimental validation of next generation therapeutic targets and integrating the targets into drug discovery campaigns. In addition, this program aims to de-risk potential therapeutics to the point that industry will invest in them, accelerating the delivery of new drugs to AD patients. To this end, the funded Centers will 1) design, develop and disseminate tools that support target enabling packages (TEPs) for the experimental validation of novel, next generation therapeutic targets, including those emanating from the NIA-funded, target discovery programs such as AMP-AD, and 2) initiate early stage drug discovery campaigns against the enabled targets.  

This Funding Opportunity Announcement (FOA) invites applications proposing research on the specific role of aging biology in the development, etiology and treatment of Alzheimer's disease. Aging is by far the main risk factor for most chronic diseases, a fact recognized by the field of geroscience. Recent advances in the fields of basic aging biology and geroscience now allow researchers to address mechanistically the role of aging in Alzheimers disease. Applications that make use of geroscience principles and test the role of different hallmarks of aging biology are specifically appropriate, while those focused solely on aging biology, or solely on Alzheimers disease will be deemed unresponsive to the FOA.

This Funding Opportunity Announcement (FOA) invites applications proposing research on the specific role of aging biology in the development, etiology and treatment of Alzheimer's disease. Aging is by far the main risk factor for most chronic diseases, a fact recognized by the field of geroscience. Recent advances in the fields of basic aging biology and geroscience now allow researchers to address mechanistically the role of aging in Alzheimers disease. Applications that make use of geroscience principles and test the role of different hallmarks of aging biology are specifically appropriate, while those focused solely on aging biology, or solely on Alzheimers disease will be deemed unresponsive to the FOA.

This FOA invites revision, resubmission, or renewal applications to the Longitudinal Early-onset Alzheimers Disease Study (LEADS) Cooperative Agreement. Revision applications may not request funding beyond the project end date of the Parent award.

This Funding Opportunity Announcement (FOA) supports concerted efforts that take a multipronged, team science strategy and apply high throughput, genome-wide approaches to systematically discover and characterize functional genomic and epigenomic elements; and elucidate and validate their functional roles and mechanisms of action underpinning the heterogeneity, pathogenesis, and progression of Alzheimers disease andrelated dementias (AD/ADRD).

The purpose of this FOA is to stimulate research on the role of environmental exposure in neurodegenerative disease (ND) by developing feasibility data for new concepts or by adapting new technologies, tools and methods of use for studies in neurodegenerative diseases. The emphasis for this FOA would be especially focused on Alzheimers (AD), Amyotrophic Lateral Sclerosis and Parkinson's (PD) to stimulate advancement of neurodegenerative research by better establishing the importance of environmental exposure in disease causation in accordance with the goals of the new strategic plan.

The purpose of this funding opportunity announcement (FOA) is to support research establishing a link between environmental exposure and the risk for Alzheimers disease (AD). Research is encouraged ranging from basic mechanistic exposure studies to human-based studies. This new effort seeks to promote work to further the understanding of the combined roles of exposure and processes implicated in AD such as inflammation and genetic susceptibility.

This FOA invites applications proposing to study health disparities in Alzheimers disease (AD) and related disorders. Health-disparities research related to AD should include the study of biological, behavioral, sociocultural, and environmental factors that influence population level health differences.

The Alzheimer's Drug Discovery Foundation is accepting Letters of Intent for its ADDF-Harrington Scholar Program, which seeks to accelerate innovative research with the potential to prevent, treat, or cure Alzheimer's disease or related dementias. The award will provide recipients with both research funding and committed project support by a team of pharmaceutical industry experts. The program aims to support hit-to-lead optimization through investigational new drug (IND)-enabling studies. Award amounts will average $600,000 over two years. In 2019, drug targets related to proteostatis are of high priority, including but not limited to autophagy, lysosomal biogenesis, proteasomal degradation, post-translational modifications associated with proteostasis, protein folding/misfolding, endoplasmic reticulum stress, and extracellular clearance. Other novel targets are encouraged, including but not limited to neuroprotection, inflammation, vascular function, mitochondria and metabolic function, APOE, and epigenetics.

The Diagnostics Accelerator program was created in July 2018 with initial funding commitments totaling nearly $35 million from a variety of partners, including ADDF co-founder Leonard Lauder, Bill Gates, the Dolby family, and the Charles and Helen Schwab Foundation. Since its inception, the program has welcomed additional funders, including the Association for Frontotemporal Degeneration and, most recently, Jeff and MacKenzie Bezos, bringing current program funding to nearly $50 million. Through this RFP, ADDF seeks proposals for the development and validation of digital biomarkers for Alzheimer's disease and related dementias. Digital biomarkers are defined as objective, quantifiable physiological and behavioral data that are collected, measured, and analyzed by means of digital devices such as portables, wearables, or ambient sensors. They can range from computerized or app-based versions of traditional neurocognitive tests to novel technology platforms that combine multiple complex data sources into a phenotypic signature.

The National Institute on Aging (NIA) solicits research projects that would advance our understanding of how protein homeostasis (proteostasis) in peripheral tissues affects brain aging, leading to the development of Alzheimers Disease (AD). Much research on AD has focused on the accumulation of aberrant protein aggregates in the brain, and in particular amyloid and Tau. Formation of aggregates due to mutations encoded in the APP gene or due to hyperphosphorylation, respectively, have been linked to familial AD. The etiology of the more common, sporadic form of AD, is less certain, although aging is considered a major risk for development of the disease. It is known that proteostasis is less efficiently maintained in all tissues with aging, and this may indicate a link between proteostasis in the periphery and the appearance of aging-related diseases and conditions, including the decline in cognitive function, as well as dementia and AD. Therefore, testing for a role of aging-related loss of peripheral proteostasis in the development of AD is the focus of this FOA.

This Funding Opportunity Announcement (FOA) invites applications that propose Artificial Intelligence (AI), Machine Learning (ML), and/or Deep Learning (DL) approaches, collectively referred to here as "cognitive systems," that lead to the identification of gene mutations/variants that cause or contribute to the risk of or protection against the development of Alzheimers disease (AD) and Alzheimer's disease related dementias (ADRD) via analysis of a variety of genetic, genomic, and biomarker data that are currently available to the research community.

This Funding Opportunity Announcement (FOA) invites applications proposing to conduct research involving pragmatic clinical trials into improving the effectiveness of treatment strategies for comorbid conditions that occur frequently in combination with Alzheimers disease and Alzheimer's disease-related dementias (AD/ADRD).

Clinical trials for Alzheimer's disease and related dementias have been hindered, in part, by the limited number of biomarkers available to (1) accurately diagnose these diseases, (2) enrich and stratify patient cohorts, (3) demonstrate target engagement for novel therapeutics, and (4) reliably monitor disease progression and response to treatment. While currently available biomarkers have helped to accelerate clinical trials, most are either expensive, invasive, or both, and provide information on a small number of disease targets. Thus, additional biomarkers are needed to provide a more complete picture of the disease.

The National Institute on Aging is seeking applications to develop systems biology approaches to understand the basic biology underpinning neurodegeneration which might ultimately contribute to Alzheimer's disease or related dementias, using non-mammalian laboratory animal models. It is expected that research carried under the auspices of this FOA will lead to discovery of new mechanisms that provoke neurodegeneration and to new molecular pathways that might be involved in causing, amplifying or protecting against neurodegeneration. Applications should propose to use established non-mammalian laboratory animals which have a history of contributions to our understanding of neurobiology or aging biology.  

This FOA invites applications on descriptive, basic and translational studies of APOE2 to delineate the functional effects of ApoE2 on healthy aging of the brain and other tissues. The primary focus is on the "APOE2-Aging-AD" relationship and the mechanistic effects of the protective variant on aging and potential interaction/cross talk between tissues in the aging process and AD. These studies are expected to generate new mechanistic insights that involve brain and/or other organs and assist in the identification of potential prognostic and diagnostic markers and therapeutic targets for AD and other age-related cognitive disorders. Eventually, the findings from these studies could lead to translational research opportunities not only to prevent or delay the onset of AD, but also to protect against multiple age-related conditions.  

This FOA is soliciting research projects that would advance biomedical research on the role of peripheral proteostasis on brain structure and function during aging and in Alzheimer's disease, facilitating the identification of molecular and cellular markers of normal brain aging and brain aging during pathological conditions.

The goal of this funding opportunity announcement is to enable the identification of the longitudinal progression of Alzheimer's disease in adults with Down Syndrome using clinical, cognitive, imaging, genetic and biochemical biomarkers. 

The goal of the fund is to encourage exploratory and developmental AD research projects within the United States. This is accomplished by providing financial support for the early and conceptual plans of those projects that may not yet be supported by extensive preliminary data but have the potential to substantially advance biomedical research. These projects should be distinct from those designed to increase knowledge in a well established area unless they intend to extend previous discoveries toward new directions or applications.